Previous 10 |
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Mark Donohue - Vice President, Investor Relations and Corporate Communications Rob Stewart - President and Chief Executive Officer Todd Branning - Chie...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ): Q4 Non-GAAP EPS of $0.33 beats by $0.06 ; GAAP EPS of -$0.07 misses by $0.32 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BRIDGEWATER, N.J. , Feb. 28, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and year ended December 31, 2018 . Executive Commentary "We ended a year o...
AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...
BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the U.S. financial markets. ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...